- Home
- CLLS vs CAF Comparison
CLLS vs CAF Comparison
Compare CLLS & CAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLLS | CAF |
|---|---|---|
| Founded | 1999 | 2006 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 394.4M | 334.0M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | CLLS | CAF |
|---|---|---|
| Price | $3.22 | $19.63 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.33 | N/A |
| AVG Volume (30 Days) | ★ 32.4K | 32.0K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 1.02% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.98 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.35 | $13.25 |
| 52 Week High | $5.48 | $20.57 |
Technical Indicators
Market Signals| Indicator | CLLS | CAF |
|---|---|---|
| Relative Strength Index (RSI) | 37.61 | 50.86 |
| Support Level | $3.05 | $19.14 |
| Resistance Level | $3.83 | $20.41 |
| Average True Range (ATR) | 0.17 | 0.34 |
| MACD | -0.03 | -0.14 |
| Stochastic Oscillator | 24.19 | 40.38 |
Price Performance
Historical ComparisonAbout CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About CAF Morgan Stanley China A Share Fund Inc.
Morgan Stanley China A Share Fund Inc is the United States based non-diversified, closed-end management investment company. Its investment objective is to seek capital growth by investing a majority of its assets in A-shares of Chinese companies listed on the Shanghai and Shenzhen Stock Exchanges. Its portfolio of investments consists of investment in different sectors such as the aerospace and defense, banks, automobiles, household durables, media, pharmaceuticals, software and other sectors.